Search Bar & Filters
Found 38 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.
Actively Recruiting
Researchers are studying the effectiveness and safety of combining inavolisib with a cyclin-dependent kinase 4 and 6 inhibitor CDK46i and letrozole compared to placebo with CDK46i and letrozole. This study focuses on adults with endocrine-sensitive PIK3CA-mutated hormone receptor-positive, HER2-negative advanced breast cancer. The trial is a phase III, randomized, double-blind, placebo-controlled study aiming to improve first-line treatment options for this condition. Participants will be randomly assigned to receive either oral inavolisib once daily alongside letrozole and a CDK46 inhibitor or a matching placebo with letrozole and CDK46 inhibitor. The CDK46 inhibitor is given on either days 1-21 or days 1-28 of each 28-day treatment cycle. Both groups will follow this treatment regimen throughout the study period. During the trial, participants will be monitored regularly to assess progression-free survival, overall survival, and various measures of treatment response and quality of life, including pain and physical function. Safety will be closely tracked by recording adverse events and treatment-related symptoms using patient-reported outcomes. The study may last up to seven years, including long-term follow-up to evaluate the effects of the treatments over time.
Actively Recruiting
Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.
Actively Recruiting
Researchers are evaluating treatments for newly diagnosed multiple myeloma in patients who cannot undergo autologous stem cell transplantation. This Phase 3 study compares two drug combinations belantamab mafodotin with lenalidomide and dexamethasone BRd versus daratumumab with lenalidomide and dexamethasone DRd. The goal is to see if BRd extends progression-free survival and improves minimal residual disease negative status compared to DRd. Participants receive either BRd or DRd treatment, continuing until disease progression, death, unacceptable side effects, withdrawal, or study end. Both treatment arms involve the administration of lenalidomide and dexamethasone alongside either belantamab mafodotin or daratumumab. Treatment duration may last up to approximately seven years. During the study, participants will undergo regular assessments including monitoring disease progression, response to treatment, and side effects. Measurements include progression-free survival, overall survival, and the number achieving minimal residual disease negative status. Quality of life questionnaires and blood tests will also be conducted. Safety monitoring includes eye exams and tracking adverse events throughout the study duration.
Actively Recruiting
Researchers are evaluating the combination of calderasib and pembrolizumab as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation and a PD-L1 tumor proportion score of 50% or higher. The study aims to determine if this combination improves progression-free survival compared to pembrolizumab with placebo. This is a phase 3 randomized, double-blind trial sponsored by Merck Sharp & Dohme LLC. Participants will receive pembrolizumab 200 mg through intravenous infusion on the first day of each 21-day cycle, continuing for up to 35 cycles. In addition, they will take either calderasib or placebo tablets daily until they meet discontinuation criteria. The study includes two groups one receiving calderasib plus pembrolizumab and the other receiving placebo plus pembrolizumab. No new participants will be offered a second course of pembrolizumab. Throughout the study, participants will undergo various assessments including tumor evaluations by central review to measure progression-free survival, overall survival, and response rates. Quality of life and physical functioning will be monitored using standardized questionnaires up to 24 months. Safety will be tracked by recording adverse events and treatment discontinuations for up to approximately 80 months. The total study duration extends up to 7 years, with ongoing monitoring throughout.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of several investigational long-acting antibody treatments, both alone and in combination, for adults with moderately to severely active ulcerative colitis UC. This Phase 2 platform study involves multiple centers and aims to improve treatment options for this condition by comparing different therapies. The study consists of two parts. Part A was an open-label phase assessing safety and early effectiveness of three monotherapies, which completed enrollment in April 2026. Part B is currently enrolling and is a randomized, placebo-controlled phase testing three monotherapies and three combination therapies against placebo. Participants will receive intravenous induction and subcutaneous maintenance treatments, with different dosing regimens evaluated over time. Participants will be monitored through regular assessments including endoscopy and histology to measure disease activity and response. The main outcomes include clinical remission and histologic improvement after 12 weeks, with longer-term remission assessed up to 48 weeks. Safety and efficacy data will be collected throughout, with treatment duration and follow-up determined by study protocol. The total study completion is expected by March 2028.
Actively Recruiting
Researchers are evaluating sacituzumab tirumotecan alone and in combination with pembrolizumab compared to the Treatment of Physicians Choice TPC in participants with hormone receptor positivehuman epidermal growth factor receptor-2 negative HRHER2- unresectable locally advanced or metastatic breast cancer. The study aims to determine if these treatments improve progression-free survival PFS based on standardized tumor response criteria, with a focus on participants who have progressed after endocrine therapy and are chemotherapy candidates. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given every two weeks by intravenous infusion until disease progression or stopping, sacituzumab tirumotecan plus pembrolizumab the latter given every six weeks by intravenous infusion for up to approximately two years, or a physicians choice of chemotherapy including options such as paclitaxel, nab-paclitaxel, capecitabine, or liposomal doxorubicin with varying dosing schedules. Treatments continue until disease progression or discontinuation. Throughout the study, participants undergo regular assessments including tumor imaging reviewed by a blinded independent central review to evaluate progression-free survival up to about 40 months. Additional measures include overall survival, response rates, quality of life questionnaires, and safety monitoring for adverse events over extended follow-up periods up to about 95 months. The study involves scheduled visits for treatment administration and monitoring, with data collected on health status, physical and emotional functioning, and treatment tolerability.
1-10 of 38
1